Copanlisib
- Generic Name
- Copanlisib
- Brand Names
- Aliqopa
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28N8O4
- CAS Number
- 1032568-63-0
- Unique Ingredient Identifier
- WI6V529FZ9
- Background
Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was gr...
- Indication
Copanlisib is indicated for the treatment of adults with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. This indication was granted under accelerated approval; thus, continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- Associated Conditions
- Relapsed Follicular Lymphoma
- Associated Therapies
- -
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
- Conditions
- Interventions
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Inhye Ahn
- Registration Number
- NCT04685915
Copanlisib Plus Venetoclax in R/R DLBCL
- Conditions
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 48
- Registration Number
- NCT04572763
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸City of Hope Cancer Center, Duarte, California, United States
🇺🇸Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT04462471
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan-Kettering Cancer Center (All protocol activities), New York, New York, United States
🇺🇸Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, United States
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT04431635
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 37
- Registration Number
- NCT04433182
- Locations
- 🇮🇹
Azienda Ospedaliera Sant'Andrea - Ematologia, Roma, Italy
🇮🇹Centro Riferimento Oncologico - S.O.C. Oncologia Medica A, Aviano, Pordenone, Italy
🇮🇹I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1, Padova, Italy
Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL
- Conditions
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 62
- Registration Number
- NCT04263584
- Locations
- 🇩🇪
Klinikum-Bremen-Mitte, Bremen, Germany
🇩🇪University Hospital RWTH Aachen, Aachen, Germany
🇩🇪St.-Johannes-Hospital Dortmund, Dortmund, Germany
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Brown University
- Target Recruit Count
- 13
- Registration Number
- NCT04253262
- Locations
- 🇺🇸
Helen Diller Family Comprehensive Cancer Center University of California San Francisco, San Francisco, California, United States
🇺🇸Lifespan Cancer Institute, Providence, Rhode Island, United States
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Columbia University
- Registration Number
- NCT04233697
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 12
- Registration Number
- NCT04156828
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 1
- Registration Number
- NCT04155840
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.